Results 11 to 20 of about 34,914 (256)
BJS (British Journal of Surgery), EarlyView., 2020 Recommendations for clinical and molecular identification of LS, surgical and endoscopic management of LS‐associated colorectal cancer and preventive measures for cancer were produced. The emphasis was on surgical and gastroenterological aspects of the cancer spectrum.
T. T. Seppälä +18 more
wiley +1 more source
Clinical Medicine Insights: Case Reports, 2018 Lynch syndrome is an autosomal dominant syndrome that can be subdivided into Lynch syndrome I, or site-specific colonic cancer, and Lynch syndrome II, or extracolonic cancers, particularly carcinomas of the stomach, endometrium, biliary and pancreatic ...
Raffaella Liccardo +2 more
doaj +1 more source
Успехи молекулярной онкологии, 2019 Lynch syndrome was synonymous with hereditary non-polyposis colorectal cancer for a long time, however, mapping of the DNA mismatch repair (MMR) genes has led to distinguish Lynch syndrome as an independent syndromic unit from a number of Lynch-like ...
A. V. Semyanikhina +2 more
doaj +1 more source
Frontiers in Oncology, 2022 BackgroundPatients with Lynch syndrome are at an increased risk of developing simultaneous or metachronous tumors, while sarcomas have been occasionally reported.
Jiaying Liu +8 more
doaj +1 more source
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018 Lynch syndrome (LS) is an autosomal-dominant disease characterized by an increased cancer susceptibility, particularly of the colon and endometrium. LS is caused by a constitutional heterozygous loss-of-function mutation or epimutation in one of the DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6 or PMS2).
Elena M. Stoffel +2 more
openaire +3 more sources
Molecular subtype classification of urothelial carcinoma in Lynch syndrome
Molecular Oncology, 2018 Lynch syndrome confers an increased risk for urothelial carcinoma (UC). Molecular subtypes may be relevant to prognosis and therapeutic possibilities, but have to date not been defined in Lynch syndrome‐associated urothelial cancer. We aimed to provide a
Christina Therkildsen +6 more
doaj +1 more source
IDH1 mutated low grade astrocytoma occurring in MSH2 mutated Lynch syndrome family
Human Pathology: Case Reports, 2016 Lynch syndrome (LS) is an autosomal dominant tumour predisposition syndrome caused by a germline mutation in one of the DNA mismatch repair (MMR) genes.Patients with these mutations have an increased risk of brain tumours, the vast majority of which are ...
Alaa Alkhotani +4 more
doaj +1 more source
Differentiating Lynch-Like From Lynch Syndrome [PDF]
Gastroenterology, 2014 Lynch syndrome is a hereditary condition found in ~3% of all colorectal cancer patients and is defined by germline inactivation in one of the DNA mismatch repair (MMR) genes (hMSH2, hMLH1, hMSH6, hPMS2) (1,2). One allele is inactivated in every cell in a Lynch syndrome patient most commonly by pathogenic mutation or deletion of hMSH2 or hMLH1, or less ...
openaire +2 more sources
Clinical, anamnestic, molecular and genetic criteria for Lynch syndrome
Успехи молекулярной онкологии, 2019 Lynch syndrome is the most common cancer-prone syndrome associated with a high risk of colorectal cancer (CRC), neoplasms of the upper gastrointestinal system, the urinary tract, the female reproductive system, brain tumours and others.
A. V. Semyanikhina +5 more
doaj +1 more source
An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome
Clinical and Experimental Gastroenterology, 2021 Christina Therkildsen,1,2 Lars Henrik Jensen,3 Maria Rasmussen,2 Inge Bernstein4,5 1Department of Surgical Gastroenterology, Copenhagen University Hospital, Copenhagen, Denmark; 2The Danish HNPCC Register, Department of Clinical Research, Copenhagen ...
Therkildsen C +3 more
doaj